NewAmsterdam Pharma (NAMS): Market Value

The price action of NewAmsterdam Pharma (NAMS) reflects market expectations regarding the success of obicietrapib, where the results of Phase 3 trials and FDA approval will serve as key drivers. The company's environmental profile is constrained by strict compliance with bio-waste disposal regulations, and its market capitalization stands at 2.42. The current business model is characterized by high risks, as the absence of commercial sales renders cash flows extremely volatile.

NAMS NewAmsterdam Pharma Company N.V.: Market Capitalization in the range 06/21/2023 - 11/15/2026

Comprehensive metric breakdowns and analytics for NewAmsterdam Pharma (NAMS)

- current price and projected stock value:

Stock Price NewAmsterdam Pharma Company|NAMS - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value NewAmsterdam Pharma Company|NAMS - Real Price to Acquire Entire Company

- book value of equity indicators:

Net Assets per Single Share NewAmsterdam Pharma|NAMS - Book Valuation of Business|Market Value to Book Value Ratio newamsterdampharma.com|NAMS - Total Asset Value of Company

- debt level and financial liquidity data:

Total Debt to Capital NewAmsterdam Pharma|NAMS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital newamsterdampharma.com|NAMS - Company Aggregate Debts|Debt to Book Capitalization Ratio NewAmsterdam Pharma Company|NAMS - Company Long-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma|Quick Ratio newamsterdampharma.com

- business earnings and investment ratios data:

NAMS - Net Profit|Future Profit NewAmsterdam Pharma|NAMS - Company Value to Net Income|Future Price to Earnings newamsterdampharma.com|NAMS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple NewAmsterdam Pharma Corp|NAMS - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months NewAmsterdam Pharma|NAMS - Earnings per share for the last four quarters|Quarterly EPS earnings growth newamsterdampharma.com|NAMS - Earnings growth in current year|Earnings growth forecast for next year NewAmsterdam Pharma

- sales volume and revenue indicators:

NAMS - Company Revenue|Company Projected Revenue newamsterdampharma.com|NAMS - Price to Sales|Price-to-Projected Revenue Ratio NewAmsterdam Pharma Company N.V.|NAMS - Sales Growth YoY (Last Twelve Months)

Fundamental company analysis:NAMS (NewAmsterdam Pharma N.V.)

Product sample of NewAmsterdam Pharma Corp

For asset stress testing, it is critical for an investor to evaluate the total value of all shares, calculated daily based on the closing price to determine the actual market value of the business. Given the lean structure of NewAmsterdam Pharma (NAMS) with maximum outsourcing of clinical trials, the company's market capitalization reflects market confidence in the value of patentable molecules rather than operational capacity, signaling potential overpayment risks.

Key competitors